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Editorial
High-dose chemotherapy for ovarian cancer: Are we ready to go?
"The wise man doesn't give the right answers, he poses the right questions."
-Claude Levi-Strauss
Sixty to seventy percent of patients with invasive epithe-
lial ovarian cancer have chemotherapy-sensitive tumors.
Nevertheless, despite excellent responses most of the
tumors eventually recur and the patients die of the
disease. Numerous mechanisms have been invoked to
explain the emergence of drug resistance, one of them
being inadequate dose intensity during the initial treat-
ment resulting in the selection of resistant cell clones.
An increase of the dose of chemotherapy is the logical
consequence of this observation.
Prior to the 'taxane era' several randomized trials
investigating platinum dose intensity failed to demon-
strate benefit for moderate increases in chemotherapy
dosage without stem cell support [1-7]. The standard
regimens in these trials usually contained cisplatin at a
dosage of 50 mg/m2 or carboplatin at a projected area
under the curve (AUC) of 4-6 mg/ml • min. Only the
Scottish trial reported that a higher dose of cisplatin
(100 mg/m2) yielded an advantage in terms of survival
[8]. This study, however, has been criticized for the
unexplained poor outcome of the patients in the lower
dose arm. Overall, there is still no evidence from
randomized trials suggesting that an increase of the
dose intensity of cisplatin beyond 25 mg/m2/week or
of carboplatin beyond an AUC of 6 mg/ml-min every
three weeks is beneficial [9].
At this time, we are not aware of any randomized
clinical trial that would provide support for using higher
than standard doses of paclitaxel.
those of the recently reported North American
registry study [13].
• Clinical data were often unavailable: the extent of
residual cancer after surgery or before beginning
high-dose therapy was unknown for a relevant
proportion of patients. The amount of residual
tumor might have an important prognostic value
as illustrated by the substantially different out-
comes reported by Legros (59% DFS at five years)
[14] and Stiff (less than 20% DFS at five years) [15].
• Toxicity data show a considerable percentage of
procedure-related deaths (7%). Similar results
have been reported by Stiff (11%) [13]; in recent
years, however, mortality decreased substantially
to 3% with improvements in supportive measures.
This paper clearly demonstrates that high-dose che-
motherapy is feasible and reasonably safe in patients
with ovarian cancer. The results in terms of survival are
comparable to those in chemosensitive recurrences re-
ported by Rose (median progression free survival nine
months) using a standard dose paclitaxel/carboplatin
regimen [16]. Unfortunately, the current retrospective
registry analysis does not allow the definition of sub-
groups for which high-dose therapy is more effective
than conventional therapy.
In the light of the development of high-dose chemo-
therapy in breast cancer, the authors of this report on
the same type of treatment for ovarian cancer are to be
commended for avoiding the error of drawing premature
The paper by Ledermann et al. in this issue [10]-^Lconclusions but for embarking on a randomized con-
reports on one of the largest series of patients treated
with high-dose chemotherapy in ovarian cancer. Most
of these patients have received high-dose chemotherapy
in phase II studies or outside of a clinical trial. Health
agencies seem to be prepared to finance expensive treat-
ments outside the context of clinical research, although
they are still reluctant to support the same therapies
within randomized clinical trials.
The paper reveals a few weak points that are unavoid-
able in this type of retrospective study:
• The data come from a registry report; therefore,
the selection of patients is heterogeneous, and it
is very likely that only patients with a relatively
favorable prognosis were selected, as in similar
previous studies in breast cancer [11, 12]. Never-
theless, the treatment results in terms of recur-
rence-free and overall survival are very similar to
trolled trial comparing modern conventional chemo-
therapy with high-dose treatment with autologous stem
cell support. Their effort merits the full support of the
oncology community.
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